摘要
目的观察地塞米松联合孟鲁司特钠治疗儿童过敏性紫癜(HSP)的疗效。方法选取医院2015年至2017年收治的HSP患儿62例,随机分为观察组(地塞米松+孟鲁司特钠治疗)与对照组(地塞米松治疗),各31例。结果观察组中有1例脱落,其余患儿皮疹消退时间、关节症状缓解时间、腹痛缓解时间、尿常规异常恢复时间均显著短于对照组(P <0. 05);观察组治疗有效率为93. 33%,显著高于对照组的67. 74%(P <0. 05);治疗2周后,两组患儿血清C-反应蛋白(CRP)、免疫球蛋白A(IgA)、白细胞介素4(IL-4)水平均显著降低(P <0. 05),且观察组显著低于对照组(P <0. 05);治疗3个月后,两组患儿β2微球蛋白(β2-MG)、转铁蛋白(TRF)水平均显著降低(P <0. 05),且观察组显著低于对照组(P <0. 05);观察组不良反应发生率为10. 00%,显著低于对照组的35. 48%(P <0. 05)。结论地塞米松联合孟鲁司特钠可有效缓解HSP的临床症状,保护肾脏,提高治疗有效率,且用药安全性高。
Objective To observe the clinical effect of dexamethasone combined with montelukast sodium in the treatment of children patients with Henoch-Schonlein purpura(HSP).Methods Totally 62 children patients with HSP admitted to our hospital from 2015 to 2017 were randomly divided into the observation group(dexamethasone combined with montelukast sodium)and the control group(dexamethasone),31 cases in each group.Results In the observation group,1 case was shed and the other cases were involved in the entire study,and the rash disappearance time,joint symptom remission time,abdominal pain remission time and recovery time of abnormal urine routine in the observation group were significantly shorter than those in the control group(P<0.05).The effective rate of treatment in the observation group was 93.33%,which was significantly higher than 67.74%in the control group(P<0.05).After 2 weeks of treatment,the levels of serum C-reactive protein(CRP),immunoglobulin-A(IgA)and interleukin-4(IL-4)in the two groups were significantly decreased(P<0.05),and those in the observation group were significantly lower than those in the control group(P<0.05).After 3 months of treatment,the levels ofβ2-microglobulin(β2-MG)and transferrin(TRF)in the two groups were significantly decreased(P<0.05),and those in the observation group were significantly lower than those in the control group(P<0.05).The incidence rate of adverse reactions in the observation group was 10.00%,which was significantly lower than 35.48%in the control group(P<0.05).Conclusion Dexamethasone combined with montelukast sodium can effectively relieve the clinical symptoms of children patients with HSP,protect their kidneys,and improve the effective rate of treatment,and it has high medication safety.
作者
张玲玲
李聚龙
赵妙
李翠环
范翠卿
ZHANG Lingling;LI Julong;ZHAO Miao;LI Cuihuan;FAN Cuiqing(Ningjin County Maternal and Child Health Care Hospital,Xingtai,Hebei,China 055550)
出处
《中国药业》
CAS
2019年第5期64-66,共3页
China Pharmaceuticals
基金
河北省2017年度医学科学研究重点课题计划[20171482]
关键词
地塞米松
孟鲁司特钠
儿童过敏性紫癜
临床疗效
dexamethasone
montelukast sodium
children patients with Henoch-Schonlein purpura
clinical effect
